• Hui Guan, Guohua Dai, Ning Wang, Wulin Gao, Lili Ren, and Zhenhao Cai.
• First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine.
• Medicine (Baltimore). 2020 Oct 16; 99 (42): e22754.

BackgroundHeart failure (HF) is the terminal stage of various common cardiovascular diseases with quite a frequent readmission and a high mortality rate, and brings heavy financial burdens to families and society. Oral Chinese patent medicine (CPM) has been widely applied in the treatment of HF in China because of its simplicity, cheapness, convenience, and high efficiency. However, due to the large number and broad clinical selectivity of oral CPMs, there is a lack of uniformity and clinical application standardization. To choose more effective and safe medicine among so many oral CPMs is particularly essential for further improving the therapeutic effect. In this study, the efficacy and safety of different oral CPMs will be compared by a network meta-analysis (NMA), and the best CPM will be selected for the treatment of HF.MethodsAccording to the search strategy, 4 English and 4 Chinese databases will be searched from the construction of the library to July 31, 2020. The NMA will include clinical randomized controlled trials (RCTs) of different oral CPMs in HF treatment. The methodological quality is assessed according to the bias risk assessment tool of Cochrane. The Bayesian NMA is performed by Aggregate Data Drug Information System (ADDIS), and the results are visualized using Stata 15.0 software. The GRADE approach is used to assess the quality of evidence and recommendation intensity.ResultsThe NMA will identify the best oral CPM in the complementary treatment of HF. A peer-reviewed journal will publish the results of the study.ConclusionThis study can provide reliable evidence for the efficacy and safety of oral CPMs in the treatment of HF, and help decision-makers and patients to select more effective and safer oral CPM.Protocol Registration NumberINPLASY202090053.

26 keywords...

hide…